Beatriz Donghia Coutinho
Psychiatry · Miami, FLNPI 1245449198
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.7% of the total across 272 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 17 manufacturers reported payments, led by Neurocrine Biosciences, Inc. at 26.6% of the total. Reporting peaked in 2019 at $1,900 and has fallen 81.8% since, to $347 in 2025. Among psychiatry clinicians in FL with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 272 payments — averaging $32.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Neurocrine Biosciences, Inc.$2K
- Teva Pharmaceuticals USA, Inc.$2K
- AbbVie$1K
- Otsuka America Pharmaceutical, Inc.$993
- Sunovion Pharmaceuticals Inc.$685
- Johnson & Johnson$564
- plus $1K from 11 others
What the payments were for
- Food & beverage$8,698100%
- Education$300%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Neurocrine Biosciences, Inc. | 45 | $2,321 |
| Teva Pharmaceuticals USA, Inc. | 37 | $1,539 |
| AbbVie(2 entities) | 48 | $1,203 |
| Otsuka America Pharmaceutical, Inc. | 42 | $993 |
| Sunovion Pharmaceuticals Inc. | 28 | $685 |
| Johnson & Johnson | 23 | $564 |
| Alkermes, Inc. | 17 | $361 |
| Indivior Inc. | 13 | $340 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 3 | $149 |
| Axsome Therapeutics, Inc. | 2 | $146 |
| E.r. Squibb & Sons, L.L.C. | 5 | $142 |
| Supernus Pharmaceuticals, Inc. | 1 | $128 |
| Shire North American Group Inc | 3 | $59 |
| Lundbeck LLC | 2 | $45 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $20 |
| Vanda Pharmaceuticals Inc. | 1 | $17 |
| Ironshore Pharmaceuticals Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$8,728 in reported general payments places this provider in the 90th percentile of 2,059 psychiatry providers in Florida.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Haloperidol Decanoate | 22 | $960 |
| Quetiapine Fumarate | 74 | $945 |
| Ziprasidone Hcl | 15 | $910 |
| Hydroxyzine Hcl | 69 | $735 |
| Mirtazapine | 35 | $630 |
| Trazodone Hcl | 68 | $606 |
| Divalproex Sodium | 29 | $460 |
| Quetiapine Fumarate ErQuetiapine Fumarate | 12 | $445 |
| Risperidone | 30 | $439 |
| Aripiprazole | 22 | $381 |
| Sertraline Hcl | 71 | $306 |
| Olanzapine | 23 | $297 |
| Benztropine Mesylate | 20 | $204 |
| Clonazepam | 46 | $199 |
| Escitalopram Oxalate | 38 | $143 |
Paid to pharmacies, not to this prescriber.
Other psychiatry in Miami
- Kenny PerezMiami$453K
- Erik CabreraMiami$357K
- Miguel FloresMiami$176K
- Pedro RodriguezMiami$96K
- John NewcomerMiami$96K
- Patricia JunqueraMiami$80K
- Marc AgroninMiami$66K
- Andrew CutlerLakewood Ranch$5.7M
- Richard JacksonBoca Raton$3.6M
- Ilan MelnickCoral Gables$2.8M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.